BCRX — BioCryst Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- $1.68bn
- $2.25bn
- $331.41m
- 35
- 37
- 91
- 53
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 48.8 | 17.8 | 157 | 271 | 331 |
Cost of Revenue | |||||
Gross Profit | 44.7 | 16.1 | 150 | 264 | 327 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 148 | 195 | 279 | 419 | 464 |
Operating Profit | -99.5 | -177 | -122 | -148 | -133 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -109 | -183 | -182 | -244 | -226 |
Provision for Income Taxes | |||||
Net Income After Taxes | -109 | -183 | -184 | -247 | -227 |
Net Income Before Extraordinary Items | |||||
Net Income | -109 | -183 | -184 | -247 | -227 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -109 | -183 | -184 | -247 | -227 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.942 | -1.08 | -1.23 | -1.33 | -1.08 |